Literature DB >> 31907372

Frontline immunotherapy for NSCLC - the tale of the tail.

Anne C Chiang1, Roy S Herbst2.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 31907372     DOI： 10.1038/s41571-019-0317-y

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  18 in total

1.  Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.

Authors:  Emmanuel Acheampong; Michael Morici; Afaf Abed; Samantha Bowyer; Du-Bois Asante; Weitao Lin; Michael Millward; Elin S Gray; Aaron B Beasley
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-28       Impact factor: 4.322

2.  Evaluation of Epidermal Growth Factor Receptor Gene Mutations in an Iranian Population with Non-Small Cell Lung Carcinoma.

Authors:  Hamzeh Salmani; Mahin Yahyaei; Reza Raoofian; Shiva Irani; Iman Salahshouri Far; Seyed Mohammad Akrami
Journal:  Iran J Public Health       Date:  2022-02       Impact factor: 1.479

3.  Case Report: A Programmed Cell Death-1 Inhibitor-Related Abdominal Fibroinflammatory Reaction Affecting Multiple Organs in A Non-Small-Cell Lung Cancer Patient.

Authors:  An-Tian Chen; Yue-Quan Shi; Bei Tan; Liang Zhu; Ya-Ping Luo; Wei Zhong; Meng-Zhao Wang; Yan Xu
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

Review 4.  Immuno-Imaging (PET/SPECT)-Quo Vadis?

Authors:  Carsten S Kramer; Antonia Dimitrakopoulou-Strauss
Journal:  Molecules       Date:  2022-05-23       Impact factor: 4.927

Review 5.  Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.

Authors:  Jamie E Chaft; Andreas Rimner; Walter Weder; Christopher G Azzoli; Mark G Kris; Tina Cascone
Journal:  Nat Rev Clin Oncol       Date:  2021-04-28       Impact factor: 65.011

6.  ROCK1 knockdown inhibits non-small-cell lung cancer progression by activating the LATS2-JNK signaling pathway.

Authors:  Ting Xin; Wei Lv; Dongmei Liu; Yongle Jing; Fang Hu
Journal:  Aging (Albany NY)       Date:  2020-06-17       Impact factor: 5.682

Review 7.  Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo.

Authors:  Gitte Holmen Olofsson; Agnete Witness Praest Jensen; Manja Idorn; Per Thor Straten
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

8.  PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors.

Authors:  Foteinos-Ioannis Dimitrakopoulos; Achilleas Nikolakopoulos; Anastasia Kottorou; Fotini Kalofonou; Elias Liolis; Theodora Frantzi; Ioannis Pyrousis; Angelos Koutras; Thomas Makatsoris; Haralabos Kalofonos
Journal:  Cancers (Basel)       Date:  2020-05-16       Impact factor: 6.639

Review 9.  Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer.

Authors:  Monika Pradhan; Mathieu Chocry; Don L Gibbons; Boris Sepesi; Tina Cascone
Journal:  Transl Lung Cancer Res       Date:  2021-01

10.  Overall Survival in Heart Disease-Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study.

Authors:  Mohammed Safi; Ravindran Kanesvaran; Mohammed Alradhi; Abdullah Al-Danakh; Feng Ping; Najeeb Al-Sabai; Xiu Shan; Jiwei Liu
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.